Back

Empagliflozin in patients with myocardial infarction: an updated meta-analysis

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in myocardial infarction Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Mohamed Abouzid

Poznan University of Medical Sciences, Poznan (Poland)

5 More presentations in this session

Presentation thumbnail
Long-term outcomes of beta-blocker use in elderly patients without left ventricular systolic dysfunction after percutaneous coronary intervention for acute myocardial infarction
Assistant Professor J. Choe (Pusan, KR)
Abstract Slides
Presentation thumbnail
The effect of discontinuing long-term beta-blockers following acute myocardial infarction in optimally treated, stable patients without heart failure - a Danish, nationwide cohort study
Doctor A. Halili (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Influence of cholesterol levels on NSAID-associated risks after myocardial infarction: a nationwide population-based cohort study
Mr M. Basem Abdallah (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction: data from SGLT2-I AMI PROTECT Registry
Doctor P. Paolisso (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study
Doctor A. Aimo (Pisa, IT)
Abstract Slides

Access the full session

Session thumbnail
Pharmacotherapy in myocardial infarction

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Effect of empagliflozin on no-reflow in patients with st elevation myocardial infarction undergoing primary percutaneous coronary intervention
thumbnail
Congress Presentation
Empagliflozin significantly reduces the capacity of sera to induce endothelial dysfunction in Ischemia Non-Obstructive Coronary Arteries (INOCA): EMbArk phase II pilot trial
thumbnail
Congress Presentation
Beneficial effects of the SGLT2 inhibition on oxidative skeletal muscle in infarcted rats

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources